Engineered biocatalysts and methods for synthesizing chiral amines

Patent metadata

Field	Value
Publication number	US-12305201-B2
Application number	US-202318344690-A
Country	US
Kind code	B2
Filing date	Jun 29, 2023
Priority date	Dec 21, 2012
Publication date	May 20, 2025
Grant date	May 20, 2025

Abstract

The present disclosure provides engineered transaminase polypeptides for the production of amines, polynucleotides encoding the engineered transaminases, host cells capable of expressing the engineered transaminases, and methods of using the engineered transaminases to prepare compounds useful in the production of active pharmaceutical agents.

First claim

What is claimed is:

1. An engineered polypeptide having transaminase activity, wherein said engineered polypeptide comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 2 and one or more residue differences as compared to SEQ ID NO:2 at residue positions selected from: X19, X34, X53, X73, X88, X107, X155, X165, X171, X178, X251, X259, X268, X277, X286, X312, X358, X366, X383, X399, X414, X426, and X450.

2. The engineered polypeptide of claim 1 , wherein said one or more amino acid residue differences as compared to SEQ ID NO: 2 are selected from X34A, X88H, X107G, X153C, X155V, X315G, X383I, and X450S.

3. The engineered polypeptide of claim 1 , wherein said engineered polypeptide comprises one or more amino acid residue differences as compared to SEQ ID NO:2 selected from X31M, X57F/L, X153A, and X383V.

4. The engineered polypeptide of claim 3 , wherein said engineered polypeptide comprises one or more amino acid residue differences as compared to SEQ ID NO:2 selected from X34A, X88A; X153C, X155V, X163F, and X315G.

5. The engineered polypeptide of claim 1 , wherein said engineered polypeptide comprises an amino acid residue difference as compared to SEQ ID NO:2 at position X316 selected from cysteine, phenylalanine, glycine, asparagine, serine and threonine.

6. The engineered polypeptide of claim 1 , wherein said engineered polypeptide comprises an amino acid residue difference as compared to SEQ ID NO:2 at position X323 of threonine.

7. The engineered polypeptide of claim 6 , wherein said engineered polypeptide comprises one or more amino acid residue differences as compared to SEQ ID NO:2 selected from X31M, X57F, X383I/T, and X450S.

8. The engineered polypeptide of claim 6 , wherein said amino acid differences as compared to SEQ ID NO:2 comprise a combination of amino acid residue differences selected from:
X31M, X57F, and X383V;
X31M, X57F, X107G, and X450S;
X31M, X57F, X233V, X383I, and X450S; and
X31M, X57F, X383I, and X450S.

9. The engineered polypeptide of claim 1 , wherein said engineered polypeptide has at least 1.2 fold increased stability as compared to the polypeptide of the amino acid sequence of SEQ ID NO: 4, wherein said engineered polypeptide comprises one or more amino acid residue differences as compared to SEQ ID NO:2 selected from X34T, X107G, X155V, X383I/V, and X450S.

10. The engineered polypeptide of claim 1 , wherein said engineered polypeptide has at least 1.2 fold increased stability as compared to the polypeptide of the amino acid sequence of SEQ ID NO: 4, wherein said engineered polypeptide comprises one or more amino acid residue differences as compared to SEQ ID NO:2 selected from X88H, and X153C.

11. The engineered polypeptide of claim 1 , wherein said engineered polypeptide has increased enantioselectivity as compared to the polypeptide of the amino acid sequence of SEQ ID NO: 4 in converting compound (2)

to compound (1),

wherein said engineered polypeptide comprises the amino acid residue differences as compared to SEQ ID NO:2 X57F and X153C.

12. The engineered polypeptide of claim 1 , wherein said engineered polypeptide comprises at least one amino acid residue difference as compared to SEQ ID NO:2 selected from: X18A, X19W, X31M, X34A, X53M, X57C/F/L, X73R, X88H/Y, X107G, X146L, X153A/C/V, X155A/V, X163L, X165F, X171Q, X178W, X190K, X206K, X228G, X235P, X244T, X251V, X259V, X268A, X277A, X286C/H, X312N, X314N, X315G, X319N, X358K, X366H, X383C/F/I/L/M/T/V, X395P, X399A, X424A, X426R, X427Y, and X450S.

13. The engineered polypeptide of claim 1 , wherein said engineered polypeptide does not comprise an amino acid residue difference as compared to SEQ ID NO:2 at positions corresponding to positions X9, X45, X177, X211, X294, X324, and X391.

14. The engineered polypeptide of claim 1 , wherein said engineered polypeptide is immobilized on a solid support.

15. The engineered polypeptide of claim 14 , wherein said solid support is a bead or resin comprising polymethacrylate with epoxide functional groups, polymethacrylate with amino epoxide functional groups, styrene/DVB copolymer or polymethacrylate with octadecyl functional groups.

16. An engineered polynucleotide encoding the engineered polypeptide of claim 1 .

17. An expression vector comprising the engineered polynucleotide of claim 16 .

18. A host cell comprising the expression vector of claim 17 .

19. A method of preparing an engineered polypeptide, comprising culturing the host cell of claim 18 , under conditions suitable for expression of said engineered polypeptide.

20. The method of claim 19 , further comprising isolating the engineered polypeptide.

Assignees

• Codexis Inc

Inventors

• Tang Weng Lin
• Hsieh Helen
• Pham Son
• Smith Derek
• Collier Steven J

Classifications

• C12Y206/01

  Transaminases (2.6.1) · CPC title

• C12P13/001

  Amines; Imines · CPC title

• C12P17/12

  containing a six-membered hetero ring · CPC title

• C12P15/00

  Preparation of compounds containing at least three condensed carbocyclic rings {(gibbanes C12P27/00; naphthacenes C12P29/00)} · CPC title

• C12P33/00

  Preparation of steroids · CPC title